Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jan;20(1):40-50.
doi: 10.1007/s00586-010-1541-4. Epub 2010 Jul 31.

A systematic review on the effectiveness of pharmacological interventions for chronic non-specific low-back pain

T Kuijpers  1 , M van Middelkoop, S M Rubinstein, R Ostelo, A Verhagen, B W Koes, M W van Tulder
Affiliations

A systematic review on the effectiveness of pharmacological interventions for chronic non-specific low-back pain

T Kuijpers et al. Eur Spine J. 2011 Jan.

Abstract

The objective of this review was to determine the effectiveness of pharmacological interventions [i.e., non-steroid anti-inflammatory drugs (NSAIDs), muscle relaxants, antidepressants, and opioids] for non-specific chronic low-back pain (LBP). Existing Cochrane reviews for the four interventions were screened for studies fulfilling the inclusion criteria. Then, the literature searches were updated. Only randomized controlled trials on adults (≥18 years) with chronic (≥12 weeks) non-specific LBP and evaluation of at least one of the main clinically relevant outcome measures (pain, functional status, perceived recovery, or return to work) were included. The GRADE approach was used to determine the quality of evidence. A total of 17 randomized controlled trials was included: NSAIDs (n = 4), antidepressants (n = 5), and opioids (n = 8). No studies were found for muscle relaxants; 14 studies had a low risk of bias. The studies only reported effects on the short term (<3 months). The overall quality of the evidence was low. NSAIDs and opioids seem to lead to a somewhat higher relief in pain on the short term, as compared to placebo, in patients with non-specific chronic low back pain; opioids seem to have a small effect in improving function for a selection of patients who responded with an exacerbation of their symptoms after stopping their medication. However, both types of medication show more adverse effects than placebo. There seems to be no difference in effect between antidepressants and placebo in patients with non-specific chronic LBP.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flow diagram of inclusion and exclusion of articles for pharmacological interventions for chronic low back pain
See this image and copyright information in PMC

References

    1. Andersson GB. Epidemiological features of chronic low-back pain. Lancet. 1999;354(9178):581–585. doi: 10.1016/S0140-6736(99)01312-4. - DOI - PubMed
    1. Hart LG, Deyo RA, Cherkin DC. Physician office visits for low back pain frequency, clinical evaluation, and treatment patterns from a U.S. national survey. Spine. 1995;20:11–19. doi: 10.1097/00007632-199501000-00003. - DOI - PubMed
    1. Vogt MT, Kwoh CK, Cope DK, Osial TA, Culyba M, Starz TW. Analgesic usage for low back pain: impact on health care costs and service use. Spine. 2005;30:1075–1081. doi: 10.1097/01.brs.0000160843.77091.07. - DOI - PubMed
    1. Roelofs PDDM, Deyo RA, Koes BW, Scholten RJPM, van Tulder MW (2008) Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev (1):CD000396. doi:10.1002/14651858.CD000396.pub3 - PMC - PubMed
    1. Van Tulder M, Touray T, Furlan AD, Solway S, Bouter LM (2003) Muscle relaxants for non-specific low-back pain. Cochrane Database Syst Rev (4):CD004252. doi:10.1002/14651858.CD004252 - PMC - PubMed

Publication types

MeSH terms

Substances